Chi-Biotech Launches Free Next-Generation Sequencing Analysis Solution Based on FANSe on Amazon’s Cloud Platform

This development enables gene sequencing companies and research institutes around the world to benefit from accurate and efficient analysis services while complying with the legal requirements of each country, which means reduced costs and increased efficiency for care. health and research.

Shenzhen, China, September 22, 2022 /PRNewswire/ — Chi-Biotech Co. Ltd. (“Chi-Biotech” or “the Company”) announced that after two years of effort, it has successfully deployed its FANSe-based next-generation sequencing analysis solution on Amazon Web Services (AWS). The free and accurate solution is now available for customers around the world, which can significantly reduce costs and increase efficiency in precision medicine and scientific research worldwide.

Next-generation sequencing (NGS) sequences billions of DNA fragments in parallel. Aligning these reads to the reference genome is the first step in almost all biomedical applications. Therefore, accuracy and speed are both essential. As instruments and experimental procedures have long been standardized, current algorithmic pipelines are far from satisfactory: repeated testing of the same sample often yields completely different results, and analysis often takes days. Chi-Biotech has developed FANSe series algorithms to address these issues. It prioritizes precision without compromising speed. In common applications such as genomic mutation calling and transcriptome quantification, it outperforms traditional algorithms such as Burrows-Wheeler Alignment (BWA) and Bowtie in accuracy and robustness, while being extremely fast. In 2020, he set the world record for analyzing human whole genome mutations in just five minutes on a single computer, and still holds it today.

FANSe requires high-end server hardware to reach its extreme speeds, making it difficult for small businesses and individuals to run it on their own computers. This led Chi-Biotech to start establishing a cloud platform in 2014 to provide one-click NGS analysis services to customers. Nowadays, most NGS analyzes on Chi-Biotech’s cloud platform are free and open to the public, so customers do not need to purchase their own servers or master complicated bioinformatics knowledge. A growing number of international customers have expressed interest in using this remarkable algorithm and cloud platform. To better serve these international companies, Chi-Biotech has cooperated with AWS to run FANSe-based NGS analysis on local AWS data centers to meet legal requirements that sequencing data must not be transferred internationally. .

Dr. Gong Zhang, co-founder of Chi-Biotech, said, “NGS analysis based on FANSe has now been established on the AWS public cloud platform. It solved the major problem of network bandwidth. Many users can upload their sequencing data simultaneously. , unleashing the extreme efficiency of the FANSe algorithm. Results are available within minutes of upload when calling enough server nodes. FANSe does not require any hardware acceleration such as Field Programmable Gate Arrays (FPGAs) or Graphics Processing Units (GPUs), which means AWS can deploy this algorithm in all of its current servers anywhere in the world at no additional cost , and can be easily updated for new application demands. The entire medical and scientific community around the world can enjoy our ultra-fast and accurate algorithm completely free of charge. People will get more accurate and cheaper genetic testing using our system. »

About Chi-Biotech

Chi-Biotech is a biotechnology company based in the Guangdong-Hong Kong-Macau Greater Bay Area. With state-of-the-art omics technology, Chi-Biotech offers comprehensive omics solutions: genomics – transcriptomics – translatomics – proteomics, with high accuracy and speed, aiming at more accurate and cost-effective precision medicine and health management. Chi-Biotech participates in the Human Proteome Project (HPP), offers services from its key resource pillar and operates the official neXtProt database in Asia. Chi-Biotech also develops creative products in the field of in vitro diagnostics (IVD) and innovative medicine.

SOURCE Chi-Biotech Co. Ltd.

Comments are closed.